These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 21464643)

  • 1. Dabigatran etexilate: the first oral anticoagulant available in the United States since warfarin.
    Tran A; Cheng-Lai A
    Cardiol Rev; 2011; 19(3):154-61. PubMed ID: 21464643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.
    Baetz BE; Spinler SA
    Pharmacotherapy; 2008 Nov; 28(11):1354-73. PubMed ID: 18956996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dabigatran etexilate: an oral direct thrombin inhibitor for the management of thromboembolic disorders.
    Cheng JW; Vu H
    Clin Ther; 2012 Apr; 34(4):766-87. PubMed ID: 22444784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial.
    Paikin JS; Haroun MJ; Eikelboom JW
    Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):279-86. PubMed ID: 21438804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dabigatran etexilate: a novel oral thrombin inhibitor for thromboembolic disease.
    Bovio JA; Smith SM; Gums JG
    Ann Pharmacother; 2011 May; 45(5):603-14. PubMed ID: 21540406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data.
    Ma TK; Yan BP; Lam YY
    Pharmacol Ther; 2011 Feb; 129(2):185-94. PubMed ID: 20920530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dabigatran: a review of clinical and pharmacoeconomic evidence.
    Reddy P; Atay JK; Selbovitz LG; Connors JM; Piazza G; Block CC; Arpino PA; Berliner N; Hutter AM; Fischer MA; Kuter D; Weitzman J; Sherwood GK; Almozlino A; Giugliano RP
    Crit Pathw Cardiol; 2011 Sep; 10(3):117-27. PubMed ID: 21989032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel oral anticoagulants: a review of the literature and considerations in special clinical situations.
    Akwaa F; Spyropoulos AC
    Hosp Pract (1995); 2013 Feb; 41(1):8-18. PubMed ID: 23466963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacology and therapeutic use of dabigatran etexilate.
    Sarah S
    J Clin Pharmacol; 2013 Jan; 53(1):1-13. PubMed ID: 23400738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Warfarin versus dabigatran etexilate: an assessment of efficacy and safety in patients with atrial fibrillation.
    Dzeshka MS; Lip GY
    Expert Opin Drug Saf; 2015 Jan; 14(1):45-62. PubMed ID: 25341529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.
    van Ryn J; Stangier J; Haertter S; Liesenfeld KH; Wienen W; Feuring M; Clemens A
    Thromb Haemost; 2010 Jun; 103(6):1116-27. PubMed ID: 20352166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation.
    Siddiqui FM; Qureshi AI
    Expert Opin Pharmacother; 2010 Jun; 11(8):1403-11. PubMed ID: 20446854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
    Garnock-Jones KP
    Am J Cardiovasc Drugs; 2011; 11(1):57-72. PubMed ID: 21265583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness.
    Gulseth MP; Wittkowsky AK; Fanikos J; Spinler SA; Dager WE; Nutescu EA
    Pharmacotherapy; 2011 Dec; 31(12):1232-49. PubMed ID: 22122184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dabigatran etexilate: a possible replacement for heparinoids and vitamin K antagonists?
    Guay DR
    Hosp Pract (1995); 2011 Feb; 39(1):105-25. PubMed ID: 21441766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor.
    Stangier J; Clemens A
    Clin Appl Thromb Hemost; 2009; 15 Suppl 1():9S-16S. PubMed ID: 19696042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dabigatran etexilate: A novel oral direct thrombin inhibitor.
    Blommel ML; Blommel AL
    Am J Health Syst Pharm; 2011 Aug; 68(16):1506-19. PubMed ID: 21817082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dabigatran etexilate: what do hospitalists need to know?
    Zeidan A; Faltas B; Streiff M
    J Hosp Med; 2012 Mar; 7(3):262-9. PubMed ID: 22128108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN).
    Van de Werf F; Brueckmann M; Connolly SJ; Friedman J; Granger CB; Härtter S; Harper R; Kappetein AP; Lehr T; Mack MJ; Noack H; Eikelboom JW
    Am Heart J; 2012 Jun; 163(6):931-937.e1. PubMed ID: 22709744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dabigatran etexilate: future directions in anticoagulant treatment.
    Schulman S; Reilly PA
    Clin Appl Thromb Hemost; 2009; 15 Suppl 1():32S-41S. PubMed ID: 19679590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.